Skip to Content
Søg Menu

The five-year-old Pacific trial on stage lll Non-small-cell cancer still reveals new findings.

In this MEDtalk the Chief Scientific Officer from Sarah Cannon research institute, David Speigel gives you the latest results from the five-year-old trial, that show a significant reduction in survival rates for patients.
David R. Spigel

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Michael Elmkvist Andersen

Kan ctDNA bruges som klinisk værktøj hos patienter med avanceret ikke-småcellet lungekræft?

/ Michael Elmkvist Andersen
DSKO24Lungecancer Play the Video 1:17
Vivi Quoc Nguyen

Carboplatin is a Viable Option in Treating Patients with Completely Resected Non-Small Cell Lung Cancer

/ Vivi Quoc Nguyen
DSKO24Lungecancer Play the Video 1:44
Odd Terje Brustugun

Onkologisk Forum: Highlights in Lung Cancer Treatment

/ Odd Terje Brustugun
Lungecancer Play the Video 5:22
Nathan Harrison

Interventions Designed to Reduce Lung Cancer Stigma

/ Nathan Harrison
WCLC23Lungecancer Play the Video 7:15
Peter Meldgaard

Spændende data om adjuverende behandling til ALK-translokerede patienter og lavstadiet lungecancer

/ Peter Meldgaard
ESMO23Lungecancer Play the Video 03:05
Jonathan Spicer

Perioperative Pembrolizumab Shows Significant OS in ResectableNon-Small-Cell Lung Cancer

/ Jonathan Spicer
ESMO23Lungecancer Play the Video 4:01
Masahiro Tsuboi

Efficacy of Osimertinib in resected EGFR-Mutated stage IB-IIIA NSCLC

/ Masahiro Tsuboi
Lungecancer Play the Video 7:07

CheckMate 227: 6-års data om behandling af lokalt avanceret NSCLC med Opdivo og Yervoy 

/ BestPractice Nordic
WCLC23NSCLCLungecancer

Adjuverende behandling med 3. generations EGFR-TKI kan øge progressionsfri overlevelse 

/ BestPractice Nordic
WCLC23NSCLCLungecancer
Back to top